Candel Therapeutics released new SITC26 data showing aglatimagene drove immune activation in localized prostate cancer and NSCLC. Separate linoserpaturev result

BWB News TV • 2026-11-06 15:21 UTC • By Billy Odell Tucker-Robinson

Candel Therapeutics released new SITC26 data showing aglatimagene drove immune activation in localized prostate cancer and NSCLC. Separate linoserpaturev results showed durable outcomes in a subset of recurrent glioblastoma patients.

Share this article

𝕏 X / Twitter Facebook LinkedIn WhatsApp

📚 More from Billy’s World

📰 Banking With Billy News All breaking financial news & market analysis 📚 Banking With Billy Books Deep-dive books on every financial story 💬 Join the Community discord.gg/VHxwmR5j4Y 🎥 Banking With Billy on YouTube Live streams & market commentary

Banking With Billy News Network — bankingwithbilly.com
Discord: discord.gg/VHxwmR5j4Y • YouTube: @BankingWithBilly